How should gynecomastia be evaluated and managed in a male patient on testosterone replacement therapy?

Gynecomastia in Men on Testosterone Replacement Therapy

Men on testosterone replacement therapy who develop gynecomastia should first have serum estradiol measured, and if elevated, be referred to endocrinology for evaluation of underlying hormonal imbalances before considering dose adjustment or discontinuation of testosterone. 1

Initial Evaluation When Gynecomastia Develops on TRT

Immediate Laboratory Assessment

• Measure serum estradiol in all testosterone-deficient patients who present with breast symptoms or gynecomastia prior to any changes in testosterone therapy. 1
• Men with elevated baseline estradiol measurements should be referred to an endocrinologist to determine the underlying hormonal cause. 2
• The endocrinologist will assess for testosterone deficiency, elevated estradiol levels, abnormal luteinizing hormone (LH) levels, and hyperprolactinemia. 2

Clinical Observation Period

• For men who develop gynecomastia or breast symptoms on testosterone treatment (breast pain, breast tenderness, nipple tenderness), a period of monitoring based on clinical judgment should be considered, as breast symptoms sometimes abate spontaneously. 1
• Noncyclical breast pain tends to be of shorter duration, with spontaneous resolution occurring in up to 50% of patients. 2

Physical Examination Findings

• Gynecomastia presents as a soft, rubbery, or firm mobile mass directly under the nipple and is often painful, especially when present for less than 6 months. 2
• Gynecomastia is bilateral in approximately 50% of patients. 2
• Differentiate true gynecomastia from pseudogynecomastia (fatty tissue deposition rather than glandular tissue enlargement), especially in patients with elevated BMI. 2

Understanding the Mechanism

Why TRT Can Cause Gynecomastia

• While it is not uncommon for estradiol levels to increase while patients are on testosterone therapy as total testosterone increases, clinicians should be aware that symptomatic gynecomastia or other breast symptoms are uncommon. 1
• Testosterone can be converted to estradiol through aromatization, particularly in adipose tissue, creating an estrogen-dominant environment that stimulates breast tissue growth. 3, 4
• Most cases of gynecomastia result from deficient androgen action or excessive estrogen action in the breast tissue. 4

Risk Factors on TRT

• Obesity contributes to pseudogynecomastia but can also increase true gynecomastia through peripheral conversion of androgens to estrogens. 5
• Injectable testosterone is associated with greater treatment-induced increases in hemoglobin/hematocrit and may also produce more variable estradiol levels compared to transdermal preparations. 1

Management Algorithm

Step 1: Measure Estradiol and Refer if Elevated

• If estradiol is elevated: Refer to endocrinology for comprehensive hormonal evaluation including testosterone, LH, FSH, and prolactin levels. 2
• The endocrinologist will determine whether the elevated estradiol is due to excessive aromatization, underlying testicular or adrenal pathology, or other hormonal imbalances. 2

Step 2: Observation Period (3-6 Months)

• If estradiol is normal or mildly elevated: Continue current testosterone therapy with close monitoring, as symptoms may resolve spontaneously in up to 50% of cases. 1, 2
• Reassess at 3-month intervals for symptom progression or resolution. 2

Step 3: Medical Therapy for Persistent Gynecomastia

• Estrogen receptor modulators may be considered for testosterone-deficient patients with low or low-normal LH levels who have persistent, symptomatic gynecomastia. 2
• Aromatase inhibitors (such as anastrozole) have been used successfully in case reports to treat testosterone-induced gynecomastia by blocking the conversion of testosterone to estradiol. 6
• However, the European Association of Andrology does not recommend the routine use of selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or non-aromatizable androgens in the treatment of gynecomastia in general. 3

Step 4: Testosterone Dose Adjustment

• Consider dose reduction if estradiol levels are significantly elevated and symptoms persist despite observation. 1
• Switching from injectable to transdermal testosterone may reduce peak testosterone levels and subsequent aromatization to estradiol. 1
• Target mid-normal testosterone levels (500-600 ng/dL) rather than upper-normal ranges to minimize aromatization. 7

Step 5: Surgical Referral for Chronic Cases

• Surgery is the therapy of choice for patients with long-lasting gynecomastia that does not regress spontaneously or following medical therapy. 3
• Gynecomastia persisting beyond 12 months often becomes fibrotic and less responsive to medical therapy, making surgery the definitive treatment. 5

Imaging Considerations

When Imaging Is NOT Needed

• For men with clinical findings consistent with gynecomastia, no imaging is routinely recommended. 2
• Most men with breast symptoms can be diagnosed based on clinical findings without imaging. 2
• Unnecessary imaging in clear cases of gynecomastia can lead to additional unnecessary benign biopsies. 2, 5

When Imaging IS Indicated

• If the differentiation between benign disease and breast cancer cannot be made clinically, or if presentation is suspicious (unilateral mass, hard, fixed, or eccentric), proceed with imaging. 2
• For men 25 and older with indeterminate findings: Mammography or digital breast tomosynthesis is recommended as the initial imaging study. 2
• For men younger than 25 with indeterminate findings: Ultrasound is the initial recommended imaging study. 2

Biopsy Indications

• Core needle biopsy is superior to fine-needle aspiration in terms of sensitivity, specificity, and correct histological grading. 2
• Image-guided core biopsy is the procedure of choice for most image-detected breast lesions requiring tissue diagnosis. 2
• Male breast cancer is rare (accounting for <1% of all breast cancers, median age 63 years) but should be ruled out in suspicious cases. 2

Special Considerations

Fertility Preservation

• Men with gynecomastia who are interested in fertility should have a reproductive health evaluation performed prior to treatment, including testicular exam and serum FSH measurement. 2
• Men with testosterone deficiency who desire fertility preservation should receive gonadotropin therapy (hCG plus FSH) rather than testosterone, as testosterone causes azoospermia. 7

Monitoring Requirements

• Hematocrit must be monitored at each visit; withhold testosterone if >54% and consider phlebotomy in high-risk cases. 1, 7
• PSA levels should be monitored in men over 40 years; refer for urologic evaluation if PSA increases >1.0 ng/mL in the first 6 months or >0.4 ng/mL per year thereafter. 1, 7
• Perform digital rectal examination at each visit to assess for prostate abnormalities. 1, 7

Common Pitfalls to Avoid

• Do not immediately discontinue testosterone without first measuring estradiol and allowing an observation period, as symptoms may resolve spontaneously. 1, 2
• Do not order imaging in clinically obvious cases of gynecomastia, as this leads to unnecessary biopsies without improving outcomes. 2, 5
• Do not assume all breast enlargement is gynecomastia—differentiate true glandular gynecomastia from pseudogynecomastia (lipomastia) in obese patients. 2, 5
• Do not miss underlying pathology—proper investigation may reveal an underlying condition in 45-50% of adult gynecomastia cases. 3
• Do not use aromatase inhibitors routinely—reserve for cases with documented elevated estradiol and persistent symptoms after observation. 3, 6

Expected Outcomes

• Small but significant improvements in sexual function (standardized mean difference 0.35) are the primary benefit of testosterone therapy, not breast-related outcomes. 7
• Testosterone therapy has little to no effect on physical functioning, energy, vitality, depressive symptoms, or cognition. 7
• Gynecomastia that develops within the first 6 months of TRT has a 50% chance of spontaneous resolution with observation alone. 2
• Chronic gynecomastia (>12 months duration) becomes fibrotic and requires surgical intervention for definitive treatment. 5, 3